Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy
Callaly, Edward, Walder, Ken, Morris, Gerwyn, Maes, Michael, Debnath, Monojit and Berk, Michael 2015, Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy, Mini-reviews in medicinal chemistry, vol. 15, no. 5, pp. 355-365.
Attached Files
Name
Description
MIMEType
Size
Downloads
Title
Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy
Bipolar disorder is a common, chronic, and complex mental illness. Bipolar disorder is frequently comorbid with primary mitochondrial and metabolic disorders, and studies have implicated mitochondrial dysfunction in its pathophysiology. In the brains of people with bipolar disorder, high-energy phosphates are decreased, lactate is elevated and pH decreased, which together suggest a shift toward glycolysis for energy production. Furthermore, oxidative stress is increased, and calcium signalling dysregulated. Additionally there is downregulation of the expression of mitochondrial complexes, especially complex I. The therapeutic effects of some bipolar disorder drugs have recently been shown to be related to these mechanisms. In this review we will evaluate current research on the interactions between mitochondrial dysfunction and bipolar disorder pathology. We will then appraise the current literature describing the effects of bipolar disorder drugs on mitochondrial function, and discuss ramifications for future research.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.